No connection

Search Results

OGI vs TNXP

OGI
Organigram Global Inc.
BEARISH
Price
$1.52
Market Cap
$209.6M
Sector
Healthcare
AI Confidence
85%
TNXP
Tonix Pharmaceuticals Holding Corp.
BEARISH
Price
$14.34
Market Cap
$203.7M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
OGI
13.82
TNXP
--
Forward P/E
OGI
84.44
TNXP
-2.78
P/B Ratio
OGI
0.77
TNXP
0.75
P/S Ratio
OGI
0.75
TNXP
15.54
EV/EBITDA
OGI
47.95
TNXP
0.11

Profitability

Gross Margin
OGI
35.61%
TNXP
49.34%
Operating Margin
OGI
-5.38%
TNXP
-895.84%
Profit Margin
OGI
6.49%
TNXP
0.0%
ROE
OGI
4.64%
TNXP
-64.48%
ROA
OGI
-1.47%
TNXP
-35.71%

Growth

Revenue Growth
OGI
48.7%
TNXP
108.8%
Earnings Growth
OGI
--
TNXP
--

Financial Health

Debt/Equity
OGI
0.02
TNXP
0.01
Current Ratio
OGI
2.73
TNXP
7.42
Quick Ratio
OGI
0.62
TNXP
6.96

Dividends

Dividend Yield
OGI
--
TNXP
--
Payout Ratio
OGI
0.0%
TNXP
0.0%

AI Verdict

OGI BEARISH

OGI exhibits severe financial fragility, highlighted by a weak Piotroski F-Score of 2/9 and a negative operating margin of -5.38%. While the stock appears undervalued relative to its Graham Number ($2.21) and Price-to-Book ratio (0.77), the intrinsic value is significantly lower at $0.77. Strong top-line revenue growth of 48.7% is currently offset by a poor earnings track record and a concerning spike in Forward P/E (from 13.82 to 84.44), suggesting a projected collapse in earnings. The company is essentially a speculative play on revenue growth that has yet to prove operational sustainability.

Strengths
Strong YoY revenue growth of 48.70%
Very low leverage with a Debt/Equity ratio of 0.02
Trading below book value (P/B 0.77)
Risks
Critical financial health weakness (Piotroski F-Score 2/9)
Negative operating margin (-5.38%) indicating core business losses
Severe earnings volatility with an average surprise of -949.02% over the last 4 quarters
TNXP BEARISH

TNXP exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9 and a catastrophic operating margin of -895.84%. While the company maintains a high current ratio (7.42) and low debt, these are likely the result of aggressive equity dilution rather than operational success, as evidenced by a -100% 5-year price return. Despite a 'strong_buy' analyst consensus and high revenue growth, the lack of earnings beats (0/4 in the last year) and a total collapse in long-term shareholder value indicate a high-risk profile. The disconnect between the analyst target price ($54.33) and the fundamental decay is extreme.

Strengths
Strong YoY revenue growth of 108.80%
High liquidity with a current ratio of 7.42
Very low debt-to-equity ratio (0.01)
Risks
Extreme operational inefficiency (Operating Margin -895.84%)
Critical financial health (Piotroski F-Score 1/9)
Consistent failure to meet earnings estimates (0/4 last 4 quarters)

Compare Another Pair

OGI vs TNXP: Head-to-Head Comparison

This page compares Organigram Global Inc. (OGI) and Tonix Pharmaceuticals Holding Corp. (TNXP) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile